← Leaderboards
Martin G Sanda
University Of Michigan At Ann Arbor
$22,920,886
Attributed
$23,418,993
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,418,993 · 10
By mechanism
U01$15,408,261 · 1
R01$4,350,932 · 2
RC1$1,996,214 · 2
P50$1,234,779 · 3
P01$428,807 · 1
M01$0 · 1
Top collaborators
- Peter R Carroll2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Duxin Sun$5,692,004
- Russell S Taichman$8,193,509
- Yusuke Shiozawa$3,431,923
- Ruma V Banerjee$24,139,300
- Evan Todd Keller$23,141,123
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortMalignant Neoplasm Of ProstateMalignant NeoplasmsBaseProstateIndolentTissuesProspectiveBiopsyDetectionEarly Detection Research NetworkValidationEnrollmentFundingUrinaryValidation StudiesCommunitiesUrineAfrican AmericanMichiganProstate NeoplasmsSerumSamplingSeverities
Grant awards (52)
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern$896,463
U01 · FY2025 · CA · contact PI
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern$968,153
U01 · FY2024 · CA · contact PI
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern$720,852
U01 · FY2023 · CA · contact PI
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center$584,697
U01 · FY2021 · CA · contact PI
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center$833,721
U01 · FY2020 · CA · contact PI
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center$787,237
U01 · FY2019 · CA · contact PI
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center$861,492
U01 · FY2018 · CA · contact PI
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center$874,523
U01 · FY2017 · CA · contact PI
Emory, Harvard & Univ. of Washington Prostate Cancer Biomarker Center$930,297
U01 · FY2016 · CA · contact PI
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center$225,120
U01 · FY2015 · CA · contact PI
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center$624,712
U01 · FY2014 · CA · contact PI
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center$680,311
U01 · FY2013 · CA · contact PI
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center$689,700
U01 · FY2012 · CA · contact PI
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center$699,142
U01 · FY2011 · CA · contact PI
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center$756,597
U01 · FY2010 · CA · contact PI
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer$500,000
RC1 · FY2010 · EB · contact PI
Effectiveness of Early Stage Prostate Cancer Treatment$496,220
RC1 · FY2010 · CA · contact PI
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr$233,591
U01 · FY2010 · CA · contact PI
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr$843,497
U01 · FY2009 · CA · contact PI
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer$500,000
RC1 · FY2009 · EB · contact PI
Effectiveness of Early Stage Prostate Cancer Treatment$499,994
RC1 · FY2009 · CA · contact PI
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr$826,363
U01 · FY2008 · CA · contact PI
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr$836,628
U01 · FY2007 · CA · contact PI
Survivor QOL/Spouse Satisfaction after Prostate Therapy$222,647
R01 · FY2007 · CA · contact PI
University of Michigan O'Brien Center for Urology Research$218,781
P50 · FY2007 · DK · contact PI
University of Michigan O'Brien Center for Urology Research$23,868
P50 · FY2007 · DK · contact PI
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr$845,278
U01 · FY2006 · CA · contact PI
Survivor QOL/Spouse Satisfaction after Prostate Therapy$615,143
R01 · FY2006 · CA · contact PI
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr$689,887
U01 · FY2005 · CA
Survivor QOL/Spouse Satisfaction after Prostate Therapy$623,152
R01 · FY2005 · CA
Survivor QOL/Spouse Satisfaction after Prostate Therapy$612,250
R01 · FY2004 · CA
Survivor QOL/Spouse Satisfaction after Prostate Therapy$580,305
R01 · FY2003 · CA
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$182,503
R01 · FY2003 · CA
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$89,644
R01 · FY2003 · CA
Survivor QOL/Spouse Satisfaction after Prostate Therapy$602,982
R01 · FY2002 · CA
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$270,980
R01 · FY2002 · CA
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCER$165,355
P50 · FY2002 · CA
TARGETING PCD IN BLADDER CANCER$115,227
P01 · FY2002 · CA
RECOMBINANT VACCINIA/PSA VACCINE IN PATIENTS WITH RECURRENCE OF PROSTATE CANCER$0
M01 · FY2002 · RR
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$232,265
R01 · FY2001 · CA
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCER$165,355
P50 · FY2001 · CA
TARGETING PCD IN BLADDER CANCER$115,227
P01 · FY2001 · CA
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$18,883
R01 · FY2001 · CA
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$16,795
R01 · FY2001 · CA
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$232,996
R01 · FY2000 · CA
TARGETING PCD IN BLADDER CANCER$198,353
P01 · FY2000 · CA
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCER$165,355
P50 · FY2000 · CA
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCER$165,355
P50 · FY2000 · CA
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCER$165,355
P50 · FY2000 · CA
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCER$165,355
P50 · FY2000 · CA
MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE$50,387
R01 · FY2000 · CA
RECOMBINANT VACCINIA/PSA VACCINE IN PATIENTS WITH RECURRENCE OF PROSTATE CANCER$0
M01 · FY2000 · RR